Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Changes in MPO, NT-proBNP, and NLR Levels in MA patients

From: Clinical value of NT-proBNP, MPO, and NLR combined with echocardiography in prediction of malignant arrhythmia in elderly patients with valvular heart disease

 

Non-MA group (n = 37)

MA group (n = 13)

P

MPO (mg/L)

108.16 ± 28.41

137.51 ± 35.54

0.003

NT-proBNP (ng/L)

621.49 ± 128.36

772.13 ± 138.72

 < 0.001

NLR

5.16 ± 1.23

6.47 ± 1.47

0.002

LVEDV (mL)

80.36 ± 26.45

94.48 ± 20.32

0.082

LVESV (mL)

45.62 ± 13.16

56.94 ± 16.38

0.013

  1. MA Malignant Arrhythmias, NT-proBNP N-terminus pro-brain natriuretic peptide, MPO Myeloperoxidase, NLR Neutrophil–Lymphocyte Ratio, LVEDV Left Ventricular End-Diastolic Volume, LVESV Left Ventricular End-Systolic Volume